Dumont & Blake Investment Advisors LLC Lowers Holdings in Bristol-Myers Squibb (NYSE:BMY)

Dumont & Blake Investment Advisors LLC reduced its position in Bristol-Myers Squibb (NYSE:BMY) by 4.7% during the 1st quarter, Holdings Channel.com reports. The firm owned 9,159 shares of the biopharmaceutical company’s stock after selling 451 shares during the period. Dumont & Blake Investment Advisors LLC’s holdings in Bristol-Myers Squibb were worth $497,000 as of its most recent SEC filing.

A number of other institutional investors have also recently made changes to their positions in BMY. Westside Investment Management Inc. raised its stake in shares of Bristol-Myers Squibb by 2.9% during the 4th quarter. Westside Investment Management Inc. now owns 7,156 shares of the biopharmaceutical company’s stock valued at $367,000 after buying an additional 204 shares during the last quarter. Traynor Capital Management Inc. raised its position in Bristol-Myers Squibb by 2.8% during the first quarter. Traynor Capital Management Inc. now owns 7,672 shares of the biopharmaceutical company’s stock valued at $416,000 after acquiring an additional 207 shares in the last quarter. Fulton Breakefield Broenniman LLC boosted its position in Bristol-Myers Squibb by 4.6% in the 4th quarter. Fulton Breakefield Broenniman LLC now owns 4,744 shares of the biopharmaceutical company’s stock worth $243,000 after purchasing an additional 209 shares in the last quarter. Chapin Davis Inc. grew its stake in shares of Bristol-Myers Squibb by 1.2% during the 4th quarter. Chapin Davis Inc. now owns 18,385 shares of the biopharmaceutical company’s stock worth $943,000 after purchasing an additional 214 shares during the period. Finally, Tilson Financial Group Inc. lifted its stake in shares of Bristol-Myers Squibb by 3.7% in the 4th quarter. Tilson Financial Group Inc. now owns 6,258 shares of the biopharmaceutical company’s stock valued at $321,000 after purchasing an additional 221 shares during the period. Institutional investors and hedge funds own 76.41% of the company’s stock.

Analysts Set New Price Targets

Several analysts recently commented on BMY shares. Societe Generale lowered shares of Bristol-Myers Squibb from a “buy” rating to a “hold” rating in a research report on Monday, March 11th. StockNews.com cut Bristol-Myers Squibb from a “strong-buy” rating to a “buy” rating in a research report on Thursday. William Blair reissued a “market perform” rating on shares of Bristol-Myers Squibb in a report on Monday, April 1st. BMO Capital Markets lowered their price target on Bristol-Myers Squibb from $55.00 to $48.00 and set a “market perform” rating on the stock in a research note on Friday, April 26th. Finally, Wells Fargo & Company raised their price objective on Bristol-Myers Squibb from $51.00 to $52.00 and gave the company an “equal weight” rating in a report on Thursday, April 18th. One research analyst has rated the stock with a sell rating, fifteen have issued a hold rating and four have assigned a buy rating to the company. According to data from MarketBeat.com, Bristol-Myers Squibb has a consensus rating of “Hold” and a consensus target price of $60.00.

Bristol-Myers Squibb Stock Up 0.0 %

NYSE:BMY traded up $0.02 during midday trading on Friday, reaching $41.53. The company had a trading volume of 20,542,742 shares, compared to its average volume of 15,934,426. The stock’s fifty day simple moving average is $42.97 and its 200-day simple moving average is $48.14. The company has a current ratio of 1.11, a quick ratio of 0.99 and a debt-to-equity ratio of 2.99. Bristol-Myers Squibb has a 12-month low of $39.63 and a 12-month high of $65.38. The firm has a market capitalization of $84.19 billion, a price-to-earnings ratio of -13.40, a PEG ratio of 14.21 and a beta of 0.43.

Bristol-Myers Squibb (NYSE:BMY) last announced its quarterly earnings data on Thursday, April 25th. The biopharmaceutical company reported ($4.40) EPS for the quarter, topping analysts’ consensus estimates of ($4.53) by $0.13. Bristol-Myers Squibb had a positive return on equity of 8.83% and a negative net margin of 13.50%. The business had revenue of $11.87 billion during the quarter, compared to the consensus estimate of $11.45 billion. During the same period in the previous year, the company posted $2.05 earnings per share. The business’s revenue for the quarter was up 4.7% on a year-over-year basis. On average, sell-side analysts anticipate that Bristol-Myers Squibb will post 0.58 earnings per share for the current fiscal year.

Bristol-Myers Squibb Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Thursday, August 1st. Stockholders of record on Friday, July 5th will be given a dividend of $0.60 per share. The ex-dividend date is Friday, July 5th. This represents a $2.40 annualized dividend and a dividend yield of 5.78%. Bristol-Myers Squibb’s dividend payout ratio (DPR) is currently -77.42%.

Bristol-Myers Squibb Profile

Bristol-Myers Squibb Company discovers, develops, licenses, manufactures, markets, distributes, and sells biopharmaceutical products worldwide. It offers products for hematology, oncology, cardiovascular, immunology, fibrotic, and neuroscience diseases. The company's products include Eliquis for reduction in risk of stroke/systemic embolism in non-valvular atrial fibrillation, and for the treatment of DVT/PE; Opdivo for various anti-cancer indications, including bladder, blood, CRC, head and neck, RCC, HCC, lung, melanoma, MPM, stomach and esophageal cancer; Pomalyst/Imnovid for multiple myeloma; Orencia for active rheumatoid arthritis and psoriatic arthritis; and Sprycel for the treatment of Philadelphia chromosome-positive chronic myeloid leukemia.